Terms: = Prostate cancer AND NBN, AT-V2, 4683, ENSG00000104320, ATV, FLJ10155, NBS, AT-V1, MGC87362, NBS1 AND Diagnosis
12 results:
1. Opportunistic screening with multiphase contrast-enhanced dual-layer spectral CT for osteoblastic lesions in prostate cancer compared with bone scintigraphy.
Liu MC; Ho CC; Lin YT; Chai JW; Hung SW; Wu CH; Li JR; Liu YJ
Sci Rep; 2024 Mar; 14(1):5310. PubMed ID: 38438474
[TBL] [Abstract] [Full Text] [Related]
2.
Ma XK; Liu TL; Ren YN; Ma XP; Yao Y; Hou XG; Ding J; Wang F; Huang HF; Zhu H; Yang Z
Acta Pharmacol Sin; 2024 Feb; 45(2):436-448. PubMed ID: 37749238
[TBL] [Abstract] [Full Text] [Related]
3. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive prostate cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract] [Full Text] [Related]
4. Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability
Perera RH; Abenojar E; Nittayacharn P; Wang X; Ramamurthy G; Peiris P; Bederman I; Basilion JP; Exner AA
Nanotheranostics; 2022; 6(3):270-285. PubMed ID: 35223380
[TBL] [Abstract] [Full Text] [Related]
5. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
[TBL] [Abstract] [Full Text] [Related]
6. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.
Hirama H; Sugimoto M; Miyatake N; Kato T; Venderbos LDF; Remmers S; Shiga K; Yokomizo A; Mitsuzuka K; Matsumoto R; Osawa T; Abe T; Sasaki H; Egawa S; Ninomiya I; Hashine K; Roobol MJ; Kakehi Y
World J Urol; 2021 Jul; 39(7):2491-2497. PubMed ID: 33079252
[TBL] [Abstract] [Full Text] [Related]
7. Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer.
Lan M; Zhu L; Wang Y; Shen D; Fang K; Liu Y; Peng Y; Qiao B; Guo Y
J Nanobiotechnology; 2020 Sep; 18(1):121. PubMed ID: 32883330
[TBL] [Abstract] [Full Text] [Related]
8. Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of prostate cancer.
Wang Y; Lan M; Shen D; Fang K; Zhu L; Liu Y; Hao L; Li P
Int J Nanomedicine; 2020; 15():4289-4309. PubMed ID: 32606678
[TBL] [Abstract] [Full Text] [Related]
9. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
[TBL] [Abstract] [Full Text] [Related]
10. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
[TBL] [Abstract] [Full Text] [Related]
11. Frequency of KLK3 gene deletions in the general population.
Rodriguez S; Al-Ghamdi OA; Guthrie PA; Shihab HA; McArdle W; Gaunt T; Alharbi KK; Day IN
Ann Clin Biochem; 2017 Jul; 54(4):472-480. PubMed ID: 27555663
[TBL] [Abstract] [Full Text] [Related]
12. [Possibilities of using magnetic resonance imaging-transrectal ultrasound fusion in the diagnosis of recurrent prostate cancer].
Kapustin VV
Vestn Rentgenol Radiol; 2011; (3):53-6. PubMed ID: 22288135
[TBL] [Abstract] [Full Text] [Related]
